Devyser Diagnostics Past Earnings Performance
Past criteria checks 0/6
Devyser Diagnostics's earnings have been declining at an average annual rate of -41.7%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 21.6% per year.
Key information
-41.7%
Earnings growth rate
-38.3%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 21.6% |
| Return on equity | -13.9% |
| Net Margin | -31.7% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company
Mar 20
Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates
Feb 23Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business
Feb 22Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company
Dec 09These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts
Aug 30Devyser Diagnostics AB (publ) (STO:DVYSR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 14Revenue & Expenses BreakdownBeta
How Devyser Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 169 | -54 | 164 | 38 |
| 30 Sep 23 | 158 | -57 | 165 | 34 |
| 30 Jun 23 | 143 | -60 | 157 | 31 |
| 31 Mar 23 | 136 | -60 | 146 | 33 |
| 31 Dec 22 | 127 | -46 | 132 | 26 |
| 30 Sep 22 | 117 | -40 | 115 | 23 |
| 30 Jun 22 | 110 | -35 | 103 | 22 |
| 31 Mar 22 | 101 | -27 | 90 | 18 |
| 31 Dec 21 | 93 | -21 | 76 | 18 |
| 31 Dec 20 | 66 | -11 | 42 | 17 |
| 31 Dec 19 | 64 | 7 | 34 | 7 |
| 31 Dec 18 | 48 | 1 | 30 | 7 |
Quality Earnings: DVYSR is currently unprofitable.
Growing Profit Margin: DVYSR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DVYSR is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.
Accelerating Growth: Unable to compare DVYSR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DVYSR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: DVYSR has a negative Return on Equity (-13.92%), as it is currently unprofitable.